TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crino, L. AU - Eberhardt, W. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Herbst, R. S. AU - Baas, P. AU - Kim, D. W. AU - Felip, E. AU - Perez-Gracia, J. L. AU - Han, J. Y. PY - 2016 DA - 2016// TI - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01281-7 DO - 10.1016/S0140-6736(15)01281-7 ID - Herbst2016 ER - TY - JOUR AU - Fehrenbacher, L. AU - Spira, A. AU - Ballinger, M. AU - Kowanetz, M. AU - Vansteenkiste, J. AU - Mazieres, J. PY - 2016 DA - 2016// TI - Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00587-0 DO - 10.1016/S0140-6736(16)00587-0 ID - Fehrenbacher2016 ER - TY - JOUR AU - Rittmeyer, A. AU - Barlesi, F. AU - Waterkamp, D. AU - Park, K. AU - Ciardiello, F. AU - Pawel, J. PY - 2016 DA - 2016// TI - Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial JO - Lancet ID - Rittmeyer2016 ER - TY - JOUR AU - Reck, M. AU - Rodriguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csoszi, T. AU - Fulop, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Antonia, S. AU - Goldberg, S. B. AU - Balmanoukian, A. AU - Chaft, J. E. AU - Sanborn, R. E. AU - Gupta, A. PY - 2016 DA - 2016// TI - Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00544-6 DO - 10.1016/S1470-2045(15)00544-6 ID - Antonia2016 ER - TY - JOUR AU - Nishino, M. AU - Sholl, L. M. AU - Hodi, F. S. AU - Hatabu, H. AU - Ramaiya, N. H. PY - 2015 DA - 2015// TI - Anti-PD-1-related pneumonitis during cancer immunotherapy JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMc1505197 DO - 10.1056/NEJMc1505197 ID - Nishino2015 ER - TY - JOUR AU - Nishino, M. AU - Ramaiya, N. H. AU - Awad, M. M. AU - Sholl, L. M. AU - Maattala, J. A. AU - Taibi, M. PY - 2016 DA - 2016// TI - PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-1320 DO - 10.1158/1078-0432.CCR-16-1320 ID - Nishino2016 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Naidoo, J. AU - Wang, X. AU - Woo, K. M. AU - Iyriboz, T. AU - Halpenny, D. AU - Cunningham, J. PY - 2016 DA - 2016// TI - Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy JO - J Clin Oncol ID - Naidoo2016 ER - TY - JOUR AU - Nishino, M. AU - Giobbie-Hurder, A. AU - Hatabu, H. AU - Ramaiya, N. H. AU - Hodi, F. S. PY - 2016 DA - 2016// TI - Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2016.2453 DO - 10.1001/jamaoncol.2016.2453 ID - Nishino2016 ER - TY - JOUR AU - Uemura, M. AU - Trinh, V. A. AU - Haymaker, C. AU - Jackson, N. AU - Kim, D. W. AU - Allison, J. P. PY - 2016 DA - 2016// TI - Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0309-7 DO - 10.1186/s13045-016-0309-7 ID - Uemura2016 ER - TY - JOUR AU - Frampton, G. M. AU - Fichtenholtz, A. AU - Otto, G. A. AU - Wang, K. AU - Downing, S. R. AU - He, J. PY - 2013 DA - 2013// TI - Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing JO - Nat Biotechnol VL - 31 UR - https://doi.org/10.1038/nbt.2696 DO - 10.1038/nbt.2696 ID - Frampton2013 ER - TY - JOUR AU - Rosenberg, J. E. AU - Hoffman-Censits, J. AU - Powles, T. AU - Heijden, M. S. AU - Balar, A. V. AU - Necchi, A. PY - 2016 DA - 2016// TI - Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00561-4 DO - 10.1016/S0140-6736(16)00561-4 ID - Rosenberg2016 ER - TY - JOUR AU - Spigel, D. R. AU - Schrock, A. B. AU - Fabrizio, D. AU - Frampton, G. M. AU - Sun, J. AU - He, J. PY - 2016 DA - 2016// TI - Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies JO - J Clin Oncol VL - 34 ID - Spigel2016 ER - TY - JOUR AU - Kowanetz, M. AU - Zou, W. AU - Shames, D. S. AU - Cummings, C. AU - Rizvi, N. AU - Spira, A. I. PY - 2016 DA - 2016// TI - Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw363.25 DO - 10.1093/annonc/mdw363.25 ID - Kowanetz2016 ER - TY - JOUR AU - Greaves, M. AU - Maley, C. C. PY - 2012 DA - 2012// TI - Clonal evolution in cancer JO - Nature VL - 481 UR - https://doi.org/10.1038/nature10762 DO - 10.1038/nature10762 ID - Greaves2012 ER - TY - JOUR AU - Vogelstein, B. AU - Papadopoulos, N. AU - Velculescu, V. E. AU - Zhou, S. AU - Diaz, L. A. AU - Kinzler, K. W. PY - 2013 DA - 2013// TI - Cancer genome landscapes JO - Science VL - 339 UR - https://doi.org/10.1126/science.1235122 DO - 10.1126/science.1235122 ID - Vogelstein2013 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Ma, W. AU - Gilligan, B. M. AU - Yuan, J. AU - Li, T. PY - 2016 DA - 2016// TI - Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0277-y DO - 10.1186/s13045-016-0277-y ID - Ma2016 ER - TY - JOUR AU - Chen, K. H. AU - Yuan, C. T. AU - Tseng, L. H. AU - Shun, C. T. AU - Yeh, K. H. PY - 2016 DA - 2016// TI - Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0259-0 DO - 10.1186/s13045-016-0259-0 ID - Chen2016 ER - TY - JOUR AU - Akincilar, S. C. AU - Khattar, E. AU - Boon, P. L. AU - Unal, B. AU - Fullwood, M. J. AU - Tergaonkar, V. PY - 2016 DA - 2016// TI - Long-range chromatin interactions drive mutant TERT promoter activation JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0177 DO - 10.1158/2159-8290.CD-16-0177 ID - Akincilar2016 ER - TY - JOUR AU - Yuan, P. AU - Cao, J. L. AU - Abuduwufuer, A. AU - Wang, L. M. AU - Yuan, X. S. AU - Lv, W. PY - 2016 DA - 2016// TI - Clinical characteristics and prognostic significance of TERT promoter mutations in cancer: a cohort study and a meta-analysis JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0146803 DO - 10.1371/journal.pone.0146803 ID - Yuan2016 ER - TY - JOUR AU - Topalian, S. L. AU - Sznol, M. AU - McDermott, D. F. AU - Kluger, H. M. AU - Carvajal, R. D. AU - Sharfman, W. H. PY - 2014 DA - 2014// TI - Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.0105 DO - 10.1200/JCO.2013.53.0105 ID - Topalian2014 ER - TY - JOUR AU - Hodi, F. S. AU - Kluger, H. AU - Sznol, M. AU - Carvajal, R. AU - Lawrence, D. AU - Atkins, M. PY - 2016 DA - 2016// TI - Abstract CT001: durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/1538-7445.AM2016-CT001 DO - 10.1158/1538-7445.AM2016-CT001 ID - Hodi2016 ER - TY - JOUR AU - Kazandjian, D. AU - Suzman, D. L. AU - Blumenthal, G. AU - Mushti, S. AU - He, K. AU - Libeg, M. PY - 2016 DA - 2016// TI - FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy JO - Oncologist VL - 21 UR - https://doi.org/10.1634/theoncologist.2015-0507 DO - 10.1634/theoncologist.2015-0507 ID - Kazandjian2016 ER - TY - JOUR AU - Chen, L. AU - Han, X. PY - 2015 DA - 2015// TI - Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI80011 DO - 10.1172/JCI80011 ID - Chen2015 ER - TY - JOUR AU - Sanmamed, M. F. AU - Chen, L. PY - 2014 DA - 2014// TI - Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation JO - Cancer J VL - 20 UR - https://doi.org/10.1097/PPO.0000000000000061 DO - 10.1097/PPO.0000000000000061 ID - Sanmamed2014 ER - TY - JOUR AU - Zhang, Y. AU - Chen, L. PY - 2016 DA - 2016// TI - Classification of advanced human cancers based on tumor immunity in the MicroEnvironment (TIME) for cancer immunotherapy JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2016.2450 DO - 10.1001/jamaoncol.2016.2450 ID - Zhang2016 ER - TY - JOUR AU - Wang, J. AU - Yuan, R. AU - Song, W. AU - Sun, J. AU - Liu, D. AU - Li, Z. PY - 2017 DA - 2017// TI - PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0403-5 DO - 10.1186/s13045-017-0403-5 ID - Wang2017 ER - TY - JOUR AU - Kalaora, S. AU - Barnea, E. AU - Merhavi-Shoham, E. AU - Qutob, N. AU - Teer, J. K. AU - Shimony, N. PY - 2016 DA - 2016// TI - Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens JO - Oncotarget VL - 7 ID - Kalaora2016 ER - TY - JOUR AU - Robbins, P. F. AU - Lu, Y. C. AU - El-Gamil, M. AU - Li, Y. F. AU - Gross, C. AU - Gartner, J. PY - 2013 DA - 2013// TI - Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3161 DO - 10.1038/nm.3161 ID - Robbins2013 ER - TY - JOUR AU - Pandey, G. S. AU - Sauna, Z. E. PY - 2014 DA - 2014// TI - Pharmacogenetics and the immunogenicity of protein therapeutics JO - J Interferon Cytokine Res VL - 34 UR - https://doi.org/10.1089/jir.2012.0136 DO - 10.1089/jir.2012.0136 ID - Pandey2014 ER - TY - JOUR AU - Hirsch, F. R. AU - Suda, K. AU - Wiens, J. AU - Bunn, P. A. PY - 2016 DA - 2016// TI - New and emerging targeted treatments in advanced non-small-cell lung cancer JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31473-8 DO - 10.1016/S0140-6736(16)31473-8 ID - Hirsch2016 ER - TY - JOUR AU - Dholaria, B. AU - Hammond, W. AU - Shreders, A. AU - Lou, Y. PY - 2016 DA - 2016// TI - Emerging therapeutic agents for lung cancer JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0365-z DO - 10.1186/s13045-016-0365-z ID - Dholaria2016 ER - TY - JOUR AU - Hsueh, E. C. AU - Gorantla, K. C. PY - 2015 DA - 2015// TI - Novel melanoma therapy JO - Exp Hematol Oncol VL - 5 UR - https://doi.org/10.1186/s40164-016-0054-1 DO - 10.1186/s40164-016-0054-1 ID - Hsueh2015 ER - TY - JOUR AU - McCaughan, G. J. AU - Fulham, M. J. AU - Mahar, A. AU - Soper, J. AU - Hong, A. M. AU - Stalley, P. D. PY - 2016 DA - 2016// TI - Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0278-x DO - 10.1186/s13045-016-0278-x ID - McCaughan2016 ER - TY - JOUR AU - Alexander, G. S. AU - Palmer, J. D. AU - Tuluc, M. AU - Lin, J. AU - Dicker, A. P. AU - Bar-Ad, V. PY - 2016 DA - 2016// TI - Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0328-4 DO - 10.1186/s13045-016-0328-4 ID - Alexander2016 ER -